Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide

Journal of Autoimmunity

Volumn 34, Issue 2, 2010, Pages 87-95

  Sharabi, Amir ^a   Lapter, Smadar ^a   Mozes, Edna ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Bcl xL; Immunosuppressive molecules; Regulatory T cells; Systemic lupus erythematosus; Tolerogenic peptides

Indexed keywords

CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLYCYLTYROSYLTYROSYLTRYPTOPHYLSERYLTRYPTOPHYLISOLEUCYLARGINYLGLUTAMYLPROLYLPROLYLGLYCYLLYSYLGLYCYLGLUTAMYLGLUTAMYLTRYPTOPHYLISOLEUCYLGLYCINE; INTERLEUKIN 10; PEPTIDE; PROTEIN BCL XL; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DRUG EFFECT; EFFECTOR CELL; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 75349098582     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.06.002     Document Type: Article

References (48)

1. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 13 (1995) 513-543
2. Hughes P., Bouillet P., and Strasser A. Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr Dir Autoimmun 9 (2006) 74-94
3. Grillot D.A., Merino R., and Núñez G. Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med 182 (1995) 1973-1983
4. Kerstan A., and Hünig T. Cutting edge: distinct TCR- and CD28-derived signals regulate CD95L, Bcl-xL, and the survival of primary T cells. J Immunol 172 (2004) 1341-1345
5. Takahashi Y., Cerasoli D.M., Dal Porto J.M., Shimoda M., Freund R., Fang W., et al. Relaxed negative selection in germinal centers and impaired affinity maturation in bcl-xL transgenic mice. J Exp Med 190 (1999) 399-410
6. Amanna I.J., Dingwall J.P., and Hayes C.E. Enforced bcl-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J Immunol 170 (2003) 4593-4600
7. Strasser A., Whittingham S., Vaux D.L., Bath M.L., Adams J.M., Cory S., et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A 88 (1991) 8661-8665
8. López-Hoyos M., Carrió R., Merino J., and Merino R. Regulation of B cell apoptosis by Bcl-2 and Bcl-XL and its role in the development of autoimmune diseases. Int J Mol Med 1 (1998) 475-483
9. Zheng B., Marinova E., Switzer K., Wansley D., He H., Bheekha-Escura R., et al. Overexpression of Bcl(XL) in B cells promotes Th1 response and exacerbates collagen-induced arthritis. J Immunol 179 (2007) 7087-7092
10. Strasser A., Harris A.W., and Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67 (1991) 889-899
11. Van Parijs L., Biuckians A., and Abbas A.K. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J Immunol 160 (1998) 2065-2071
12. González J., Tamayo E., Santiuste I., Marquina R., Buelta L., González-Gay M.A., et al. CD4+CD25+ T cell-dependent inhibition of autoimmunity in transgenic mice overexpressing human Bcl-2 in T lymphocytes. J Immunol 178 (2007) 2778-2786
13. Waisman A., Shoenfeld Y., Blank M., Ruiz P.J., and Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol 7 (1995) 689-696
14. Luger D., Dayan M., Zinger H., Liu J.P., and Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 24 (2004) 579-590
15. Rapoport M.J., Sharabi A., Aharoni D., Bloch O., Zinger H., Dayan M., et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 117 (2005) 262-270
16. Sharabi A., Haviv A., Zinger H., Dayan M., and Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol 119 (2006) 146-155
17. + cells and TGF-β. Proc Natl Acad Sci U S A 103 (2006) 8810-8815
18. Sharabi A., Azulai H., Shtoeger Z.M., and Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology 121 (2007) 248-257
19. Sharabi A., and Mozes E. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 Cells that are required for the optimal induction and function of Foxp3-expressing CD4 Cells. J Immunol 181 (2008) 3243-3251
20. Sharabi A., Luger D., Ben-David H., Dayan M., Zinger H., and ad Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 179 (2007) 4979-4987
21. Bruder D., Probst-Kepper M., Westendorf A.M., Geffers R., Beissert S., Loser K., et al. Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 34 (2004) 623-630
22. Raimondi G., Shufesky W.J., Tokita D., Morelli A.E., and Thomson A.W. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 176 (2006) 2808-2816
23. Chemnitz J.M., Parry R.V., Nichols K.E., June C.H., and Riley J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173 (2004) 945-954
24. Novak E.J., Masewicz S.A., Liu A.W., Lernmark A., Kwok W.W., and Nepom G.T. Activated human epitope-specific T cells identified by class II tetramers reside within a CD4high, proliferating subset. Int Immunol 13 (2001) 799-806
25. Ridgway W., Fassò M., and Fathman C.G. Following antigen challenge, T cells up-regulate cell surface expression of CD4 in vitro and in vivo. J Immunol 161 (1998) 714-720
26. Martins S.L., St John L.S., Champlin R.E., Wieder E.D., McMannis J., Molldrem J.J., et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104 (2004) 3429-3436
27. Morrissey P.J., Charrier K., Braddy S., Liggitt D., and Watson J.D. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 178 (1993) 237-244
28. Powrie F., Correa-Oliveira R., Mauze S., and Coffman R.L. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179 (1994) 589-600
29. Chen X., Murakami T., Oppenheim J.J., and Howard O.M. Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J Immunol 34 (2004) 859-869
30. Minamimura K., Gao W., and Maki T. CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 176 (2006) 4125-4132
31. Hahn B.H., Singh R.P., La Cava A., and Ebling F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol 175 (2005) 7728-7737
32. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., et al. Cutting edge: cD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171 (2003) 3348-3352
33. Tai X., Cowan M., Feigenbaum L., and Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 6 (2005) 152-162
34. Boise L.H., González-García M., Postema C.E., Ding L., Lindsten T., Turka L.A., et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 (1993) 597-608
35. Antov A., Yang L., Vig M., Baltimore D., and Van Parijs L. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 171 (2003) 3435-3441
36. Socolovsky M., Fallon A.E., Wang S., Brugnara C., and Lodish H.F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 98 (1999) 181-191
37. Barron L., Knoechel B., Lohr J., and Abbas A.K. Cutting edge: contributions of apoptosis and anergy to systemic T cell tolerance. J Immunol 180 (2008) 2762-2766
38. Kharbanda S., Saxena S., Yoshida K., Pandey P., Kaneki M., Wang Q., et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 275 (2000) 322-327
39. Whitmarsh A.J., and Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74 (1996) 589-607
40. Wu Y., Borde M., Heissmeyer V., Feuerer M., Lapan A.D., Stroud J.C., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126 (2006) 375-387
41. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 24 (2006) 209-226
42. Zheng S.G., Wang J.H., Stohl W., Kim K.S., Gray J.D., and Horwitz D.A. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol 176 (2006) 3321-3329
43. Read S., Greenwald R., Izcue A., Robinson N., Mandelbrot D., Francisco L., et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 177 (2006) 4376-4383
44. Boussiotis V.A., Lee B.J., Freeman G.J., Gribben J.G., and Nadler L.M. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol 159 (1997) 3156-3167
45. Chen W., Jin W., Tian H., Sicurello P., Frank M., Orenstein J.M., et al. Requirement for transforming growth factor beta1 in controlling T cell apoptosis. J Exp Med 194 (2001) 439-453
46. Blair P.J., Riley J.L., Levine B.L., Lee K.P., Craighead N., Francomano T., et al. Cutting edge: cTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J Immunol 160 (1998) 12-15
47. Singh R.P., La Cava A., and Hahn B.H. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 180 (2008) 2069-2080
48. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25 (2005) 9543-9553